Marfan disease
==============

Marfan syndrome is a heritable disorder of the connective tissue with an autosomal-dominant transmission and pleiotropic manifestations involving the ophthalmologic, musculoskeletal and cardiovascular systems ([@b32]; [@b14]). It is a relatively frequent manifestation of the most common genetic disorders, estimated to affect 1 in 6,000 to 10,000 people. The exact prevalence is unknown, but 1 patient who satisfies strict diagnostic criteria is found per 10,000 patients, with no known gender or ethnic predilection.

Both medical and surgical concepts play an integrated role in the therapeutic management of cardiovascular manifestations of the Marfan syndrome and related disorders. Because of cardiovascular involvement, especially aortic dilation with subsequent dissection or rupture, Marfan syndrome is associated with significant morbidity and mortality. The first line therapeutic option for aortic pathologies in Marfan patients is the surgical reconstruction. Because Marfan syndrome is a disease of the entire aorta, there needs a close follow-up.

This article focuses on the cardiovascular aspects of Marfan syndrome and discusses the recent data on the field of endovascular stent-graft placement in Marfan patients with previous aortic surgery.

Cardiovascular manifestations
=============================

The average life expectancy of untreated patients with Marfan syndrome is 32 years ([@b29]). In \>90% of cases in which a cause of death was identifiable, the cardiovascular system was involved, and the most common cause of death was aortic dissection or aortic rupture ([@b29]). The cardiovascular manifestations, first described in 1943, are clinically apparent in 40% to 60% of patients with Marfan syndrome. Moreover 34% of patients with Marfan syndrome will have serious cardiovascular complications requiring major cardiac surgery in the first 10 years after diagnosis ([@b22]). A common factor of all phenotypic forms of aortic wall disease is the dedifferentiation of vascular smooth muscle cells not only with classic aneurysm formation, but also from enhanced elastolysis of aortic wall components. In addition, mitral valve prolapse is the most prevalent valvular abnormality, affecting 35% to 100% of patients ([@b47]). Less commonly reported abnormalities are tricuspid valve prolapse and dilatation of the main pulmonary artery. Thus, for approximately 2 decades, it has become clear that only the successful management of cardiovascular manifestations of the Marfan syndrome is likely to increase individual life expectancy. Fortunately, both medical and surgical therapies have proven capable of achieving this goal ([@b44]; [@b43]; [@b2]).

Considering the limitations of physical examination, to recognize cardiovascular abnormalities in Marfan syndrome, echocardiography, computed tomography (CT) scanning, or magnetic resonance imaging (MRI) play an important role in the diagnostic work-up. The most frequent cardiovascular manifestations include aortic root dilation and aortic dissection. Aortic dissection or rupture and aortic regurgitation most often lead to death. The ascending aorta, aortic valve, and mitral valve can be evaluated by the 2-dimensional echocardiography and color Doppler interrogation in the parasternal long-axis orientation, and measurements can be obtained with the help of M-mode echocardiography. There are, however, patients with severe pectus abnormalities in whom a technically acceptable surface echocardiogram is impossible, and even transesophageal echocardiography (TEE) may be inadequate. MRI is an excellent alternative for these patients, as well as for pregnant patients in whom echocardiography is sometimes difficult ([@b41]).

Aortic root involvement
=======================

Aortic abnormalities are found in 60% to 90% of patients with Marfan syndrome ([@b6]; [@b10]). The aortic root involvement is the classic feature with a greater prevalence in males than in females ([@b6]). The sinuses of Valsalva are usually dilated at birth and were abnormal throughout life in proportion to body surface area with a variable rate of progression during adolescence ([@b21]; [@b36]). Echocardiographic criteria for aortic root dilation as proposed by Brown and colleagues (1990) include a) width index of the aorta \>22 mm/m^2^; b) actual measurement of an aortic diameter \>40 mm; and c) left atrial to aortic diameter ratio \>0.7. Aortic diameter should be measured at the sinuses of Valsalva and related to normal values based on age and body surface area ([@b38]). Aortic dilatation may be limited to the sinus of Valsalva or may involve the proximal and mid ascending aorta and increases at a variable rate. [@b24] reported an increase in 42% of Marfan patients by 1.9 mm yearly. The severity of aortic dilatation is related to the degree of aortic dilatation and to the length of the dilated segment. Generalized aortic dilatation in patients with Marfan syndrome is a marker for increased risk of subsequent aortic complications ([@b39]). Dilatation of the aorta is accompanied in 15% to 44% by aortic regurgitation ([@b39]). A myxomatous aortic valve may also contribute to aortic regurgitation ([@b37]). Conventionally, regurgitation results from stretching of the commissures at the sino-tubular junction; therefore, at least a moderate degree of root dilation is necessary before a valvular leakage is present ([@b37]). For example, aortic regurgitation is uncommon in an adult with a maximum root dimension of 45 to 50 mm, but it is always present when the dimension is \>60 mm ([@b48]); cusp fenestrations or dissection can cause aortic regurgitation regardless of aortic dimension.

Aortic dissection
=================

The prevalence of Marfan syndrome among patients with aortic dissection is unclear but recent data from the International Registry of Aortic Dissection (IRAD) reported that 5% of the 1049 patients had this disorder ([@b27]) ([Table 1](#tbl1){ref-type="table"}). In other surveys the rate ranges between 3.2% and 5.8% ([@b51]; [@b28]). Aortic dissection generally occurs in the presence of an enlarged aortic root (\>40 mm) and is associated with a family history of dissection. Aortic dilatation and dissection are mainly observed on the proximal part of the ascending aorta, just above the coronary ostia, which is submitted to maximal hemodynamic stress and is the richest in elastic fibers as well as in fibrillin which may contribute to the pathogenesis of aortic dissection. The association between increased aneurysm diameter and the risk for dissection or rupture is clearly established so that an aneurysm size \>6 cm cause a 4-fold increase in the cumulative risk ([@b8]). However, 20% of dissections occur in patients with a normal aortic root size (\<40 mm). Less than 20% of acute dissections in patients with Marfan syndrome are type B lesions; these usually arise distal to the left subclavian artery in an often undilated descending thoracic aorta ([@b23]). Moreover pregnancy in patients with Marfan syndrome is associated with an increased risk of aortic dissection, especially during the third trimester, birth and the first month post partum ([@b33]).

###### 

Characteristics of patients with and without Marfan syndrome in the International Registry of Aortic Dissection (IRAD) ([@b27])

                                                      Marfan syndrome   Non-Marfan syndrome   p-value
  --------------------------------------------------- ----------------- --------------------- ---------
  Age (years)                                         35 ± 12           64 ± 13               \<0.001
  Systemic hypertension (%)                           27                74                    \<0.001
  Prior aortic aneurysm (%)                           33                13                    \<0.001
  Prior aortic dissection (%)                         23                4                     \<0.001
  Prior cardia surgery due to aortic dissection (%)   27                8                     \<0.001
  Prior aortic valve replacement (%)                  19                4                     \<0.001
  Sinus of Valsalva (cm)                              5,05 ± 1,75       4,11 ± 0,96           0.006
  Ascending aorta (cm)                                5,29 ± 1,75       4,77 ± 1,31           0.09
  Type A dissection (%)                               76                62                    0.04
  Intramural hematoma                                 2                 11                    0.03

Type A dissection is the leading cause of death in Marfan syndrome, most frequently through retrograde extension into the pericardium with resulting lethal tamponade ([@b29]). Acute dissection may be accompanied by all of the classic signs and symptoms, or it may be clinically silent. Some patients, however, feel that something is suddenly and definitely wrong and hurry to the emergency room where they are often misdiagnosed. Close inspection of the medical records of many such cases reveals that a life-threatening condition should have been suspected, either from the symptoms and signs or simply because the patient was known to have Marfan syndrome. The recommendations regarding timing of surgical repair have been determined, in part, by an appreciation of the risk of dissection. It has become clear recently that this risk is not the same for all aortas at a given diameter ([@b37]). A comparison between patients who sustained dissection, patients who underwent prophylactic repair of the aorta, and patients awaiting such surgery revealed that a family history of dissection is useful for stratification ([@b34]).

Indication for surgery
======================

Aortic dissection and rupture are the leading causes of morbidity and mortality in Marfan syndrome, and prophylactic surgery is recommended to prevent this complication. The indication for prophylactic aortic surgery is been predicated on aortic size and recommended when the diameter reaches 5.0 cm ([@b43]; [@b8]) or the diameter reaches twice of the adjacent segments ([@b44]; [@b43]). Factors that promptly wants the recommendation for surgery when the aorta is \<5.0 cm include rapidly growth of the aortic diameter (5%/year) ([@b2]), a family history of premature aortic dissection and the presence of greater than mild aortic regurgitation. ([Table 2](#tbl2){ref-type="table"}).

###### 

Flow chart for managment of Marfan patients with aortic disease

![](vhrm0401-59-02)

**Abbreviations:** PIE, prophylaxix of infective endocarditis; AD, aortic dissection; AR, aortic regurgitation; DP, diameter progression; EVSG, endovascular stent graft; AA, aortic aneurysm; DA, diameter of the aorta.

Indication for endovascular intervention after previous aortic surgery
======================================================================

Even after successful aortic root replacement, however, the dissected descending aorta remains a source of late complications in Marfan syndrome (von Kodolitsch et al 1994). The role of percutaneous stent-grafting for treatment of aortic pathologies in Marfan patients after aortic surgery is not established yet. In very small number of treated patients several groups could show the feasibility of stent-graft placement with good short-term results (Nienaber et al 1999; [@b25]; [@b52]; [@b15]). The aim is to avoid an enlargement of the aorta or of the false lumen by sealing the proximal entry tear with a customized stent-graft. Because of being a disease of the entire aorta, this procedure is just a therapeutic option to avoid a repeated aortic surgery. The reason for stent-graft placement against repeat aortic surgery in first line is the mortality rate of 31% for repeated aortic surgery in Marfan patients ([@b7]; [@b19], [@b20]).

Technique of endovascular stent-graft placement
===============================================

Based on diagnosed measurements obtained during angiography, transesophageal echography, or tomographic spiral CT or MRI, customized stent-grafts can be used to both scaffold up to 20 cm of dissected or dilatated aorta and cover major tears. The procedure is best performed in a hybrid laboratory with catheterization and imaging capabilities including digital angiography under general anesthesia and ventilation. The femoral artery is the most popular access-site and can usually accommodate a 24 F stent-graft system. The procedure will begin by injecting 5000 units of heparin. The femoral or distal iliac artery is surgically exposed. Using the Seldinger technique, a 260 cm, 0.89 mm (0.035 inch) stiff wire is placed over a pigtail catheter navigated with a soft wire in the true lumen under both fluoroscopic and transesophageal ultrasound guidance. In complex cases with multiple reentries in the abdominal aorta, the embracement-technique with the use of 2 pig-tail catheters is useful. A pig-tail catheter, which has been installed in the true aortic lumen via the left brachial artery, picks up the femoral pig-tail catheter in the true lumen of the abdominal aorta and pulls it up into the aortic arch. This procedure ensures definite positioning of the stiff guide wire in the true lumen, which is essential for correct deployment of the stent-graft. Carefully advanced over the stiff wire, the launching of the stent-graft is performed with systolic blood pressure lowered to 50--60 mmHg by infusion sodium nitroprusside or by rapid right ventricular pacing to avoid misplacement. After deployment short inflation of a latex balloon can improve apposition of the stent struts to the aortic wall, but only if proximal sealing of thoracic communications is incomplete. Both Doppler-ultrasound and contrast fluoroscopy are instrumental for documenting the immediate result or initiating adjunctive maneuvers. After removing the sheath and guidewire the access sites can be closed in standard fashions.

Own experiences
===============

There are only few data concerning stent-grafts to avoid repeat surgery for complicated persistent distal dissection after previous root replacement. In our institution, endovascular reconstruction of a dissected Marfan aorta was subsequently attempted in seven consecutive cases with previous root replacement and in one case with isolated type B dissection. Transluminal placement of customized stent-grafts was technically successful in 8 patients with Marfan syndrome with no 30 day or 1 year intervention-related mortality and without any signs of neurological complications ([Figure 1](#fig1){ref-type="fig"}). The follow-up ranges from 12 to 92 months (mean 63 ± 19). Mean stent-graft length was 151 ± 23 mm (range 90--180). Stent-graft procedures lasted a mean 132 ± 34 minutes (range 97--236). False lumen thrombosis was seen in 6 of 8 patients. Complete abolition of the dissection and reconstruction of the entire dissected aorta was documented in 4 patients, and conversion to elective surgical repair in 3 patients (22, 43, and 80 months after stent-graft implantation) due to enlargement of the false lumen. One patient died suddenly 12 months after endovascular repair.

![**A.** Sagittal view of a contrast enhanced computed tomography scan showing a native type B aortic dissection in a young Marfan syndrome patient; the 3 pictograms in axial view identify a small true lumen and a larger false. **B.** Gd-enhanced MR tomogram in sagittal orientation; Follow-up study one year after endovascular stent-graft placement showing no resident false lumen and reconstruction of the dissected aorta as confi rmed on axial pictograms.](vhrm0401-59-01){#fig1}

Results from the literature
===========================

In the survey performed by [@b3] 11 of 1073 patients treated with endovascular stent-graft had an arteriopathy, 6 had Marfan syndrome, 3 had Takayasu's Arteritis, and 2 had a giant cell arteritis. Eight of the 11 patients had undergone previous aortic surgery. Technical success of the endovascular stent-graft placement was achieved in 92%. Early complications like wound infection and postoperative myocardial infarction was seen in 25%. There were no perioperative mortalities or immediate conversion to open surgery ([@b3]). Elective conversion to open surgery was performed in 3 of 6 patient in the follow-up (28 and 52 month after EVSG) due to progression of the aortic disease in the entire aorta (n = 2) and due to rupture of the intercostal patch (n = 1). Similar satisfactory results with asymtomatic subjects and lacking signs for a dilatation in the treated aorta were reported in other case reports ([@b46]; [@b17]; [@b11]; [@b18]). [@b5] treated succesfully a patient with unusual rapid evolution of type B aortic dissection following heart transplantation, which had an incidence of 40% for thoracic aortic dissection. The mortality rates of endovascular stent-grafts for patients with acute aortic syndromes range from 0% to 16% while the same patients treated surgically would have a risk in the range of 40% or perhaps even exceeding up to 70% if treated medically (Fann et al 1994).

[@b40] treated a fistula at the distal anastomisis after Bentall operation with endovascular stent graft with complete occlusion of the false aneurysm documented in the control comuted tomography in a 25-year-old Marfan patient. Another 42-year-old Marfan patient with type B dissection distal from the left subclavian artery up to the right iliac artery with no lower limb pulses and a poor perfusion of the left kidney was treated by [@b53] showing complete healing in the axial imaging performed one year later with no symptoms of lower limb paralysis nor left arm claudication ([Table 3](#tbl3){ref-type="table"}).

###### 

Summary of published data from Marfan patients treated by endovascular stent-graft

                                                         [@b26]                                                       [@b3]                                       [@b17]                                  [@b5]                                        [@b11]                      [@b53]              [@b40]              [@b18]
  ------------------------------------------------------ ------------------------------------------------------------ ------------------------------------------- --------------------------------------- -------------------------------------------- --------------------------- ------------------- ------------------- --------
  n                                                      6                                                            6                                           1                                       1                                            2                           1                   1                   6
  Sex                                                    4 (m); 2 (f)                                                 6 (m)                                       1 (f)                                   n.a.                                         n.a.                        1 (m)               n.a                 n.a.
  Age                                                    33 ± 15                                                      48 ± 9                                      24                                      n.a.                                         n.a.                        42                  25                  n.a.
  Follow-up (months)                                     55 ± 22                                                      30                                          36                                      n.a.                                         16                          n.a.                n.a.                n.a.
  Baseline condition                                     Bentall (n = 4), Yacoub (n = 1), type-B-Dissection (n = 1)   Bentall (n = 4), TAA (n = 1), AAA (n = 1)   Replacement of thoracic aorta (n = 1)   Bentall and heart- transplantation (n = 1)   type-B-dissection (n = 2)   type-B-dissection   type-A-dissection   n.a.
  Technical success                                      in all                                                       in all                                      yes                                     yes                                          in both                     yes                 yes                 in all
  Perioperative mortality                                no                                                           no                                          no                                      no                                           no                          no                  no                  no
  Second intervention (n; %)                             no                                                           1 (17%)                                     no                                      no                                           no                          no                  no                  no
  Immediate conversion to surgery                        no                                                           no                                          no                                      no                                           no                          no                  no                  no
  Neurological complication                              no                                                           no                                          no                                      no                                           no                          no                  no                  no
  Mortality in follow-up (n; %)                          1(17%)                                                       no                                          no                                      no                                           no                          no                  no                  n.a.
  Elective conversion to surgery (n; month after EVSG)   3 (22, 43,74)                                                3 (28,52,n.a.)                              0                                       0                                            0                           0                   0                   n.a.

**Abbreviations:** TAA, thoracic aortic aneursym; AAA, abdominal aortic aneurysm; EVSG, endovascular stent-graft; n, number; m, male; f, female; n.a., not available.

Discussion
==========

Marfan syndrome is a generalized polymorphic inherited disease of connective tissue with large interfamilial and intrafamilial variability, complete penetrance, and autosomal dominant transmission. It is relatively common, with an incidence of 1 per 10.000 with no difference according to gender, race, or ethnicity and is clinical characterized by abnormalities of the skeletal, ocular, and cardiovascular system ([@b32]).

Before delicate aortic surgery became available on a broader scale, the majority of patients with Marfan syndrome died prematurely of aortic rupture, often in their early adulthood ([@b20]). In a survey performed by [@b29] 50% of men affected by Marfan syndrome were dead by the age of 40 years. The success of current medical and surgical treatment of aortic disease in Marfan syndrome patients has substantially improved the average life expectancy, extending it up to 70 years ([@b16]; [@b42]). [@b46] reported a trend to lower mortality risk: from 57% between 1963 and 1969, to 27% between 1990 to 1999 for surgical patients. Introduction of both (Bentall procedure [@b4], composite graft conduits, and root reconstruction eventually changed the bleak outlook for Marfan syndrome patients with aneurysm of the ascending aorta with improvement of the 10 year survival rate in prophylactic aortic root replacement up to 97% compared with 34% in patients who did not undergo surgical intervention ([@b22]). A survey in 10 major Marfan centers reported a 30-day mortality rate of 1.5% for patients undergoing elective repair of aortic root aneurysms; and 11.7% among patients requiring emergent surgery ([@b19]). Even after successful aortic root replacement, however, the dissected descending aorta remains a source of late complications in Marfan syndrome ([@b50]).

In contrast to excellent surgical results of elective root replacement, both early and long-term results of repeat surgery for the descending aorta, which is required subsequently in 10% to 27% ([@b49]), remain poor and had a mortality rate up to 31% ([@b42]; [@b19], [@b20]; [@b9]). In the report of [@b9] including 4 Marfan patients with previous aortic root surgery requiring replacement of both the thoracic and abdominal aorta for expansion or imminent rupture of the false lumen 1 patient died, a second became paraplegic, and only 2 fared well. In a recent study by [@b1] 3 of 7 patients with Marfan syndrome and late postoperative aortic complications underwent resurgery of the descending aorta after previous aortic root replacement with a 33% mortality. A larger survey reported 63 of 653 Marfan syndrome patients with previous aortic root replacement to require late aortic surgery for progressive disease; only 46 patients were alive at the time of last follow-up ([@b11]). More than half of these second interventions take place without direct anatomical relation with the preoperated aortic segment. In 40% of patients, local complications of the preoperated aorta in the area of the aorta ascendens or the aortic arch lead to an individualized second intervention ([@b49]).

The postoperative mortality rate is determined by late aortic dissection in 33% and progressive heart failure in 35% of the Marfan patients with previously aortic surgery. Five and 15 year survival rate were 71% to 88% and 71% respectively ([@b49]).

In contrast to the increased risk of repeat aortic surgery endovascular stent-graft repair could be a feasible alternative to open surgery in selected cases. To date there are only limited experiences with stent-grafts in Marfan patients ([Table 3](#tbl1){ref-type="table"}).

This limited data demonstrate not only technical feasibility, but also some therapeutic potential of endovascular stent-graft treatment in Marfan syndrome with distal dissection after complex aortic root repair or acute aortic syndrome. The technical execution of endovascular stent-graft deployment was safe, since peri- and post-interventional outcomes were favorable. Preservation of the integrity of the aorta, rather than surgical resection, has previously proven to avoid neurological events and interference with spinal artery supply ([@b35]; [@b25]). None of our patients had neurological or vascular events, although the risk of paraplegia with elective surgery of the descending aorta is estimated at 8%; such risk figures pertain to centers with special experience in aortic surgery, and to patients without any previous surgical repair of the aorta ([@b12]). Although the endovascular strategy was employed in relatively few patients and observational in nature, it revealed a feasible and relatively safe nonsurgical alternative to treat descending aortic dissection in Marfan patients after aortic surgery. Regardless of feasibility, however, conversion to surgery after stent-graft placement underlines that endovascular stent-grafting should be considered a bridging rather than curative procedure, which was also confirmed by the data of [@b3]. They could demonstrate that 2 of 6 initially successful treated patients had to be converted to surgery due to abnormalities in the entire aorta. Furthermore, with death of one patient (12 month after stent-graft implantation) who suffered from complex aortic pathology both close surveillance and repeat imaging of the aorta appear mandatory to detect silent postinterventional complications eventually requiring surgical repair.

Although conceptually promising -- considering sobering results of surgical repair ([@b45]) -- adjunctive management by stent-graft placement in distally extending dissection lacks the support of long-term follow-up data. Nevertheless, over several years of follow-up after stent-graft placement for the treatment of both thoracic and abdominal aneurysms, late adverse effects were infrequent and may justify "bridging" stent-grafts even in relatively young patients with Marfan syndrome after aortic root surgery ([@b30], [@b31]; [@b25], [@b26]; [@b45]) in the attempt to avoid the risks of (emergent) repeat surgery.

In summary, due to the lack of long-term follow-up experience and small number of cases published, endovascular stent-graft treatment may emerge in the future as a feasible therapeutic option for Marfan patients with late distal complications following aortic surgery, but clear evidence is still missing.
